Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron D Jachimowicz

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Scientific Reports|November 16, 2024
Starvation-induced metabolic rewiring affects mTORC1 composition in vivoEdgar Kaade, Simone Mausbach, Nina Erps, et al.
American Journal of Hematology|December 11, 2012
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphomaMaike Sauer, Annette Plütschow, Ron D Jachimowicz, et al.
International Journal of Cancer|September 30, 2023
Optical genome mapping identifies structural variants in potentially new cancer predisposition candidate genes in pediatric cancer patientsRabea Wagener, Danielle Brandes, Marie Jung, et al.
Frontiers in Immunology|December 21, 2023
Mouse models of diffuse large B cell lymphomaAreya Tabatabai, Aastha Arora, Svenja Höfmann, et al.
Cancer Discovery|February 22, 2014
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDCFelix Dietlein, Lisa Thelen, Mladen Jokic, et al.
Molecular Oncology|February 19, 2021
Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinomaTomohiro Murakami, Yoshiaki Shoji, Tomohiko Nishi, et al.
Molecular Cancer Therapeutics|April 29, 2011
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinomaRon D Jachimowicz, Giulio Fracasso, Paul J Yazaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase InhibitorToby A Eyre, Yuqin Song, Olivier Hermine, et al.
Leukemia|January 26, 2026
Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft modelClaus-Moritz Gräf, Moritz Reese, Angela Vicente-Luque, et al.
International Journal of Cancer|November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinomaAchim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Scientific Reports|November 16, 2024
Starvation-induced metabolic rewiring affects mTORC1 composition in vivoEdgar Kaade, Simone Mausbach, Nina Erps, et al.
American Journal of Hematology|December 11, 2012
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphomaMaike Sauer, Annette Plütschow, Ron D Jachimowicz, et al.
International Journal of Cancer|September 30, 2023
Optical genome mapping identifies structural variants in potentially new cancer predisposition candidate genes in pediatric cancer patientsRabea Wagener, Danielle Brandes, Marie Jung, et al.
Frontiers in Immunology|December 21, 2023
Mouse models of diffuse large B cell lymphomaAreya Tabatabai, Aastha Arora, Svenja Höfmann, et al.
Cancer Discovery|February 22, 2014
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDCFelix Dietlein, Lisa Thelen, Mladen Jokic, et al.
Molecular Oncology|February 19, 2021
Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinomaTomohiro Murakami, Yoshiaki Shoji, Tomohiko Nishi, et al.
Molecular Cancer Therapeutics|April 29, 2011
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinomaRon D Jachimowicz, Giulio Fracasso, Paul J Yazaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase InhibitorToby A Eyre, Yuqin Song, Olivier Hermine, et al.
Leukemia|January 26, 2026
Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft modelClaus-Moritz Gräf, Moritz Reese, Angela Vicente-Luque, et al.
International Journal of Cancer|November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinomaAchim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.
Pageof 4